ES2547698T3 - Liposoma de irinotecán o su clorhidrato y método de preparación del mismo - Google Patents
Liposoma de irinotecán o su clorhidrato y método de preparación del mismo Download PDFInfo
- Publication number
- ES2547698T3 ES2547698T3 ES09851784.0T ES09851784T ES2547698T3 ES 2547698 T3 ES2547698 T3 ES 2547698T3 ES 09851784 T ES09851784 T ES 09851784T ES 2547698 T3 ES2547698 T3 ES 2547698T3
- Authority
- ES
- Spain
- Prior art keywords
- liposome
- irinotecan
- hydrochloride
- preparation
- neutral phospholipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960004768 irinotecan Drugs 0.000 title abstract 4
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title 1
- 239000002502 liposome Substances 0.000 abstract description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 8
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 abstract description 7
- 229960000779 irinotecan hydrochloride Drugs 0.000 abstract description 6
- 235000012000 cholesterol Nutrition 0.000 abstract description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract description 3
- 230000007935 neutral effect Effects 0.000 abstract 4
- 150000003904 phospholipids Chemical class 0.000 abstract 4
- 239000006071 cream Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 4
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 4
- 238000001125 extrusion Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
Un liposoma de irinotecán o clorhidrato de irinotecán, caracterizado porque el citado liposoma comprende irinotecán o clorhidrato de irinotecán, un fosfolípido neutro y el colesterol, y la relación en peso del colesterol con el fosfolípido neutro es 1: 3~5, caracterizado porque la citada relación en peso del fosfolípido neutro con el irinotecán o clorhidrato de irinotecán es de 2~5: 1, preferiblemente 2.5 ~ 4: 1 y porque el citado fosfolípido neutro comprende la fosfatidilcolina de soja hidrogenada.
Description
- Muestra
- Tiempo de almacenamiento (25 ºC, día) Apariencia Eficiencia de encapsulación % Tamaño de partículas (z-v) nm Contenido (mg/ml) Impurezas totales % Lisofosfolipido (mg/ml)
- HSPC
- 0 Blanco crema suspensión 99.70 85.6 5.42 0.65 0.40
- 30
- Blanco crema suspensión 91.51 87.7 5.40 0.74 0.65
- HSPC+ VE
- 0 Blanco crema suspensión 97.10 89.0 5.01 0.48 0.35
- 30
- Blanco crema suspensión 93.49 93.4 5.03 0.56 0.43
- HSPC+ EDTA
- 0 Blanco crema suspensión 95.67 87.2 4.94 0.56 0.38
- 30
- Blanco crema suspensión 95.67 86.5 4.98 0.60 0.40
- HSPC+ VE+ EDTA
- 0 Blanco crema suspensión 98.92 89.2 5.55 0.61 0.39
- 30
- precipitación de partículas 87.31 99.7 5.51 0.61 0.47
Ejemplo 7
Formulación (1):
clorhidrato de irinotecán 0.5g
fosfatidilcolina de soja hidrogenada 1.5 g
colesterol 0.4 g
sulfato de manganeso 10 g
manitol 2.5 g
agua inyectable hasta el volumen requerido
5 Método de preparación:
Se disolvieron la fosfatidilcolina de soja hidrogenada y el colesterol de la cantidad de formulación en una cantidad adecuada de etanol anhidro y la solución de lípidos resultante se mezcló con solución de sulfato de manganeso (100 ml). Después el etanol anhidro se eliminó por destilación a presión reducida, se obtuvo el liposoma blanco en bruto. El tamaño de partícula del liposoma fue controlada mediante la extrusión de los liposomas en un equipo de extrusión (dos 10 membranas de extrusión de 0.1m en un equipo de extrusión de extrusión de cinco veces). El liposoma blanco fue dializado utilizando un dispositivo de ultrafiltración de flujo tangencial con complementario continuo de agua inyectable en el curso, se obtuvo entonces el liposoma blanco. La solución acuosa de clorhidrato de irinotecán se preparó con agua inyectable y se adicionó a la dispersión de liposomas blanco con gradiente iónico. Bajo agitación, la mezcla se calentó a 50 ºC y se incubó durante 20 minutos, y luego se obtuvo el liposoma cargado con un fármaco. El fármaco no 15 encapsulado se retiró mediante el uso de dispositivo de ultrafiltración de flujo tangencial y luego se adicionaron 2.5 g de manitol para ajustar la presión osmótica. Después la concentración del fármaco se ajustó por dilución con el volumen constante, el liposoma se esterilizó por filtración con filtro de 0.22 m, y luego se llenó bajo la protección de nitrógeno, y se selló en una botella pequeña. Finalmente se obtuvo la inyección de liposomas de clorhidrato de irinotecán. El tamaño de partícula del liposoma se midió por el analizador de tamaño de nano partículas (89.3nm), y la eficiencia de
20 encapsulación fue del 97.5%.
- Fármaco
- Administración Ruta Volumen medio del tumor (mm3) D0 SD Volumen medio del tumor (mm3) D12 SD RTV D12 SD % T/C D12 Tasa de inhibici ón del tumor (%) D12 Valor P D12 Regresi ón parcial Número de animales
- Vehículo
- D0,3 IV 219.8 ±37.2 2013.7 ±303.1 9.4 ±2. 3 100 0 - 0 8
- liposomas CPT11 1.0mg/kg
- D0,3 IV 212.2 ±42.1 732.2 ±162.6 3.5 ±0. 7 38 62 0.000 0 13
- liposomas CPT11 3.0mg/kg
- D0.3 IV 205.0 ±49.0 265.1 ±122.9 1.3 ±0. 4 13 87 0.000 4 13
- CPT-11 10mg/kg
- D0.3 IV 204.6 ±44.7 844.4 ±197.5 4.2 ±0. 9 45 55 0.000 0 14
- D0: la primera vez de administración; RTV: volumen tumoral relativo; P Valor medio en relación con el control. Grupo de control n = 12, Grupo de tratamiento n = 6.
Claims (1)
-
imagen1 -imagen2 imagen3
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2009/075298 WO2011066684A1 (zh) | 2009-12-03 | 2009-12-03 | 伊立替康或盐酸伊立替康脂质体及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2547698T3 true ES2547698T3 (es) | 2015-10-08 |
Family
ID=44114598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09851784.0T Active ES2547698T3 (es) | 2009-12-03 | 2009-12-03 | Liposoma de irinotecán o su clorhidrato y método de preparación del mismo |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20120282325A1 (es) |
| EP (1) | EP2508170B1 (es) |
| JP (1) | JP5645954B2 (es) |
| KR (2) | KR20120089754A (es) |
| CN (1) | CN102271659B (es) |
| AU (1) | AU2009356132B2 (es) |
| BR (1) | BR112012012151B8 (es) |
| CA (1) | CA2782911C (es) |
| CY (1) | CY1116811T1 (es) |
| DK (1) | DK2508170T3 (es) |
| ES (1) | ES2547698T3 (es) |
| HR (1) | HRP20150911T1 (es) |
| HU (1) | HUE027467T2 (es) |
| MX (1) | MX2012005775A (es) |
| PL (1) | PL2508170T3 (es) |
| PT (1) | PT2508170E (es) |
| RU (1) | RU2526114C2 (es) |
| SI (1) | SI2508170T1 (es) |
| SM (1) | SMT201500245B (es) |
| WO (1) | WO2011066684A1 (es) |
| ZA (1) | ZA201203316B (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102935066B (zh) * | 2011-08-16 | 2014-09-17 | 齐鲁制药有限公司 | 一种伊立替康脂质体制剂及其制备方法 |
| SI2768484T1 (sl) | 2011-10-21 | 2019-12-31 | Jazz Pharmaceuticals Research Llc | Liofilizirani liposomi |
| KR101842279B1 (ko) * | 2012-03-29 | 2018-03-26 | 우석대학교 산학협력단 | 이리노테칸의 안정성증진을 위한 주사제용 조성물 |
| RU2014144945A (ru) * | 2012-04-10 | 2016-05-27 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Бис-полимерные липид-пептидные конъюгаты и наночастицы из них |
| US9949927B2 (en) | 2012-04-10 | 2018-04-24 | The Regents Of The University Of California | Bis-polymer lipid-peptide conjugates and nanoparticles thereof |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| CN102697720B (zh) * | 2012-06-29 | 2014-01-15 | 海南灵康制药有限公司 | 盐酸伊立替康脂质纳米粒注射剂 |
| CN103181898B (zh) * | 2012-11-23 | 2016-03-09 | 杭州师范大学 | 一种奥沙利铂脂质体及其应用 |
| EA023079B1 (ru) * | 2012-12-24 | 2016-04-29 | Общество С Ограниченной Ответственностью "Технология Лекарств" | Способ получения липосомальной формы иринотекана (варианты) |
| CN104906586A (zh) * | 2014-03-10 | 2015-09-16 | 中国科学院上海药物研究所 | 一种盐酸伊立替康复合磷脂组合物、制备方法及其应用 |
| WO2015166986A1 (ja) | 2014-04-30 | 2015-11-05 | 富士フイルム株式会社 | リポソーム組成物及びその製造方法 |
| US10098813B2 (en) * | 2014-09-03 | 2018-10-16 | Sun Pharmaceutical Industries Limited | Perfusion dosage form |
| CN105796495B (zh) * | 2014-12-29 | 2020-10-23 | 南京绿叶制药有限公司 | 一种盐酸伊立替康脂质体药物组合物及其制备方法 |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| JP2017008047A (ja) * | 2015-06-25 | 2017-01-12 | 参天製薬株式会社 | 注射剤 |
| JP7042739B2 (ja) | 2015-08-20 | 2022-03-28 | イプセン バイオファーム リミティド | 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法 |
| TW202400181A (zh) | 2015-08-21 | 2024-01-01 | 英商益普生生物製藥有限公司 | 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法 |
| EP4647126A3 (en) | 2015-10-16 | 2026-02-11 | Ipsen Biopharm Ltd. | Stabilizing camptothecin pharmaceutical compositions |
| IL261038B2 (en) | 2016-02-09 | 2024-06-01 | Sun Pharmaceutical Ind Ltd | perfusion system |
| CN107281102A (zh) * | 2016-04-11 | 2017-10-24 | 江苏竞诺择生物医药科技有限公司 | 一种用于结直肠肿瘤治疗的药物微粒组合物 |
| CN107456456A (zh) * | 2016-06-03 | 2017-12-12 | 江苏恒瑞医药股份有限公司 | 伊立替康或其可药用盐在制备治疗乳腺癌的药物中的用途 |
| AU2017290703B2 (en) * | 2016-06-28 | 2023-03-30 | Emergent Biodefense Operations Lansing Llc | Formulations of brincidofovir |
| CN106109415B (zh) * | 2016-07-26 | 2019-01-29 | 金华市人民医院 | 一种载喜树碱类抗肿瘤药物脂质体、制备方法及其应用 |
| KR20190067172A (ko) | 2016-09-09 | 2019-06-14 | 아이리시스, 인크. | 리포좀 항암 조성물 |
| AU2017350499B2 (en) * | 2016-10-28 | 2023-08-10 | Les Laboratoires Servier | Liposomal formulation for use in the treatment of cancer |
| CN110402163A (zh) * | 2016-11-02 | 2019-11-01 | 易普森生物制药有限公司 | 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌 |
| US11344497B1 (en) | 2017-12-08 | 2022-05-31 | Quicksilver Scientific, Inc. | Mitochondrial performance enhancement nanoemulsion |
| US10722465B1 (en) * | 2017-12-08 | 2020-07-28 | Quicksilber Scientific, Inc. | Transparent colloidal vitamin supplement |
| ES2984147T3 (es) | 2018-06-20 | 2024-10-29 | Fujifilm Corp | Medicamento combinado que comprende una composición liposómica de gemcitabina encapsulada y bloqueo de punto de control inmunitario |
| CN109675047B (zh) * | 2019-01-07 | 2020-12-04 | 中国科学院化学研究所 | 一种对具有游离羟基的化合物进行脂质体修饰的方法 |
| US11291702B1 (en) | 2019-04-15 | 2022-04-05 | Quicksilver Scientific, Inc. | Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method |
| US12195755B2 (en) | 2019-05-20 | 2025-01-14 | Brown University | Placental lipid bilayer for cell-free molecular interaction studies |
| US11273124B2 (en) * | 2019-05-23 | 2022-03-15 | Brown University | Antifungal nanoparticles for targeted treatment of fungal infections |
| WO2021087008A1 (en) | 2019-10-28 | 2021-05-06 | Brown University | Bacterial beta-lactamase responsive hydrogels |
| CN114177278A (zh) * | 2021-10-18 | 2022-03-15 | 山东多美康生物医药有限公司 | 脂质体制备 |
| CN121064118A (zh) * | 2025-09-02 | 2025-12-05 | 襄阳汉伟化工科技有限公司 | 一种安全气囊填充剂5-氨基四氮唑的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6740335B1 (en) * | 1997-09-16 | 2004-05-25 | Osi Pharmaceuticals, Inc. | Liposomal camptothecin formulations |
| KR100679906B1 (ko) * | 1998-09-16 | 2007-02-07 | 알자 코포레이션 | 리포솜-엔트랩된 토포이소머라제 억제제 |
| ES2387886T3 (es) * | 2001-11-13 | 2012-10-03 | Celator Pharmaceuticals, Inc. | Composiciones que transportan lípidos con una mejor estabilidad sanguínea |
| LT3173073T (lt) * | 2004-05-03 | 2025-01-10 | Ipsen Biopharm Ltd. | Liposomos, skirtos vaistų pristatymui |
| KR100889139B1 (ko) * | 2004-06-01 | 2009-03-17 | 테루모 가부시키가이샤 | 이리노테칸 제제 |
| CN1326525C (zh) * | 2004-11-26 | 2007-07-18 | 复旦大学 | 10－羟基喜树碱长循环脂质体及其冻干制剂 |
| WO2007076117A2 (en) * | 2005-12-22 | 2007-07-05 | Celator Pharmaceuticals, Inc. | Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof |
| WO2008011427A2 (en) * | 2006-07-17 | 2008-01-24 | Syntha Corporation | Calculating and predicting performance of power generating unit |
| CN1994279A (zh) * | 2006-12-31 | 2007-07-11 | 西安力邦医药科技有限责任公司 | 注射用盐酸伊立替康脂质体的制备方法 |
| CN101019834A (zh) * | 2006-12-31 | 2007-08-22 | 西安力邦医药科技有限责任公司 | 注射用7－乙基－10羟基喜树碱脂质体的制备方法 |
| EP2146692A1 (en) | 2007-03-19 | 2010-01-27 | Fresenius Kabi Oncology Limited | Proliposomal and liposomal compositions |
| CN101283983A (zh) * | 2007-10-26 | 2008-10-15 | 南京长澳医药科技有限公司 | 一种稳定的喜树碱类药物脂质体组合物 |
-
2009
- 2009-12-03 WO PCT/CN2009/075298 patent/WO2011066684A1/zh not_active Ceased
- 2009-12-03 PT PT98517840T patent/PT2508170E/pt unknown
- 2009-12-03 JP JP2012541296A patent/JP5645954B2/ja not_active Expired - Fee Related
- 2009-12-03 MX MX2012005775A patent/MX2012005775A/es active IP Right Grant
- 2009-12-03 RU RU2012123875/15A patent/RU2526114C2/ru active
- 2009-12-03 US US13/512,048 patent/US20120282325A1/en not_active Abandoned
- 2009-12-03 HU HUE09851784A patent/HUE027467T2/en unknown
- 2009-12-03 BR BR112012012151A patent/BR112012012151B8/pt not_active IP Right Cessation
- 2009-12-03 DK DK09851784.0T patent/DK2508170T3/en active
- 2009-12-03 KR KR1020127015958A patent/KR20120089754A/ko not_active Ceased
- 2009-12-03 KR KR1020167033432A patent/KR101780915B1/ko not_active Expired - Fee Related
- 2009-12-03 ES ES09851784.0T patent/ES2547698T3/es active Active
- 2009-12-03 PL PL09851784T patent/PL2508170T3/pl unknown
- 2009-12-03 AU AU2009356132A patent/AU2009356132B2/en not_active Ceased
- 2009-12-03 CN CN2009801540269A patent/CN102271659B/zh active Active
- 2009-12-03 HR HRP20150911TT patent/HRP20150911T1/hr unknown
- 2009-12-03 CA CA2782911A patent/CA2782911C/en active Active
- 2009-12-03 EP EP09851784.0A patent/EP2508170B1/en active Active
- 2009-12-03 SI SI200931279T patent/SI2508170T1/sl unknown
-
2012
- 2012-05-08 ZA ZA2012/03316A patent/ZA201203316B/en unknown
-
2015
- 2015-10-09 SM SM201500245T patent/SMT201500245B/xx unknown
- 2015-10-21 CY CY20151100943T patent/CY1116811T1/el unknown
-
2017
- 2017-03-21 US US15/464,922 patent/US10022365B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2547698T3 (es) | Liposoma de irinotecán o su clorhidrato y método de preparación del mismo | |
| ES3056133T3 (en) | Method for selective extraction of cannabinoids from a plant source | |
| AU2019206651B2 (en) | Encapsulated cannabinoid formulations for oral delivery | |
| US11446247B2 (en) | Liposome composition and pharmaceutical composition | |
| CA2681302C (en) | Proliposomal and liposomal compositions of poorly water-soluble compounds | |
| Wang et al. | Albumin self-modified liposomes for hepatic fibrosis therapy via SPARC-dependent pathways | |
| TWI837189B (zh) | 包含內含藥物之脂質體組成物及鉑製劑之組合醫藥 | |
| US7485320B2 (en) | Liposome for incorporating large amounts of hydrophobic substances | |
| CA2879931A1 (en) | Cochleates made with soy phosphatidylserine | |
| ES2849730T3 (es) | Formulaciones liposómicas estables de rapamicina y derivados de rapamicina para tratar el cáncer | |
| CN103989624B (zh) | 一种盐酸伊立替康组合物及其制备方法 | |
| WO2012146057A1 (zh) | 一种姜黄素类化合物注射溶液及其静脉注射剂 | |
| CN108120778B (zh) | 一种嘌呤衍生物脂质体的药物含量测定方法 | |
| CN102258468A (zh) | 脂质体喷雾剂及其制备方法 | |
| CN101209251A (zh) | 含有紫杉醇或多烯紫杉醇的弹性纳米囊泡制剂及其制备方法 | |
| CN105796480B (zh) | 一种芒果苷制剂及其用途 | |
| TWI500430B (zh) | 伊立替康或鹽酸伊立替康脂質體及其製備方法 | |
| JP7724358B2 (ja) | 抗腫瘍薬を含む組成物、並びにその調製方法及びその使用 | |
| CN107184554A (zh) | 一种鼻腔纳米制剂葛根素液晶纳米粒及其制备方法 | |
| HK40045737A (en) | Combination medicine comprising drug-encapsulating liposome composition and platinum preparation | |
| US20220000797A1 (en) | Clear propofol injection and preparation method therefor | |
| Ali et al. | Preparation of methylene blue-containing nanoliposomes and determination of stability, biological distribution and drug release after sonication by 1 MHZ ultrasound waves | |
| JP2024023887A (ja) | 抗腫瘍剤 | |
| ES2932780A1 (es) | Composicion a base de quercetina (qct), epigalocatequina-3-galato (egcg), zinc y vitamina d3, como suplemento alimenticio para reforzar el sistema inmunologico | |
| EA051941B1 (ru) | Композиция, содержащая противоопухолевое лекарственное средство и способ ее получения и применение |